(Reuters) – Roche’s second-quarter adjusted operating income rose a better-than-expected 9% on higher sales of diagnostic tests and pharmaceuticals.
Core operating income, which is adjusted for one-off effects, gained 9% to 12.67 billion Swiss francs ($13.07 billion), the Swiss drugmaker said in a statement on Thursday, above an analyst consensus of 12.1 billion francs.
It confirmed its full-year guidance.
($1 = 0.9694 Swiss francs)
(Reporting by Ludwig, editing by Kirsti Knolle)
